Join Verge Genomics Diego Cadavid next week at the European Network to Cure ALS (ENCALS) in Stockholm! This is a great opportunity to get an update on Verge's unique proof-of-concept study on VRG50635, a small-molecule PIKfyve inhibitor being investigated as a potential treatment for all forms of ALS. #ALS #ENCALS24 #ALSResearch #AIDrugDiscovery
Verge Genomics
Biotechnology Research
South San Francisco, CA 14,930 followers
Better drugs, faster. For patients who can’t wait.
About us
Verge Genomics is a next-generation biopharmaceutical start-up using systems biology to accelerate development of life-saving treatments for neurodegenerative diseases. Our platform uses patient genomes, gene expression, and epigenomics to identify new therapeutic gene targets, predict effective drugs, and stratify patient subpopulations for increased clinical success. Verge's approach offers a breakthrough opportunity to identify drugs that dramatically improve patient outcomes and fundamentally lower the cost curve of pharmaceutical development. We are looking for extraordinary individuals to join our motivated team in taking on our generation’s biggest healthcare challenges: ALS, Parkinson’s Disease, and Alzheimer's Disease. Our employees are our most important asset; we are a team of founders, excited to learn, roll up our sleeves, and make a real impact. The startup nature of Verge Genomics provides multiple growth opportunities into other areas of the company. As one of the early employees at Verge, your work will have a direct impact on the foundation of a groundbreaking new drug development model. In addition to competitive compensation and benefits, we offer perks like unlimited vacation/sick days, on-site gym access, and free lunch. Verge actively seeks a diverse applicant pool in order to build the strongest possible workforce. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
- Website
-
http://www.vergegenomics.com
External link for Verge Genomics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, CA
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Bioinformatics, Genomics, Drug Discovery, and Neuroscience
Locations
-
Primary
Get directions
2 Tower Place
South San Francisco, CA 94080, US
Employees at Verge Genomics
Updates
-
We are thrilled to share an insightful article by our CEO, Alice Zhang, featured in Fortune. Alice's thoughtful perspective on leading with empathy, embracing vulnerability, and fostering a culture of transparency and trust, highlights how these principles are integral to Verge's mission and hopefully will inspire leaders across all industries. Check out the full article here: The Importance of Conscious Leadership https://lnkd.in/e5WtY966
What companies are going to prevail in this post-AI world? Those that build the right cultures. In inventive work, the best teams outperform the average ones by 10X. There is a huge premium on building creative, effective teams of the best caliber in AI. Today, I write in Fortune about how re-defining corporate culture is the most overlooked aspect of building a successful AI-enabled company. Today's leaders don't pound their fists on the table and talk about how they're crushing it. They have the courage to simply be vulnerable.
-
Meet the Verge Genomics BD Team, Michelle Mighdoll & Sam Galindo, at #BIO2024! Looking forward to connect and collaborate June 3-6, 2024. #BIO2024 #AI
-
-
Be sure to catch Verge Genomics Irene Choi at this week’s #DiscoveryEurope24 where she will share insights on how Verge's AI platform CONVERGE® is used to to identify novel targets, an overview of our proof-of-concept study for a potential ALS therapy that was discovered and developed using Verge’s AI platform and the future of AI/ML in drug discovery and beyond! Details are below. #DiscoveryEurope24 #VergeGenomics #AI #DrugDiscovery #OGDiscovery
-
-
We are thrilled that Verge Genomics' CMO Diego Cadavid is presenting at the 3rd Annual ALS Drug Development Summit on May 23rd at 11:30 AM. Diego will share insights on Verge’s groundbreaking proof-of-concept study design to evaluate VRG50635 as a potential novel therapeutic candidate for ALS. Don't miss this opportunity to learn more about VRG50635 and the future of ALS treatment! https://ter.li/qdfuop Location: Hyatt Regency Boston, 1 Ave de Lafayette, Boston, MA 02111 #ALS #ALSresearch #ALSdrugdevelopment
-
-
We're pleased to partner with Ferrer to co-develop VRG50635, our lead drug candidate for the treatment of sporadic and familial forms of #ALS. Hear our President and Chief Business Officer, Jane Rhodes, share how our #innovation and Ferrer's experience create a complementary partnership as we progress a potential treatment for this devastating disease. #biotechnology #drugdevelopment
We are delighted to announce an important news for people living with amyotrophic lateral sclerosis (ALS), their families, and their caregivers, thanks to our a strategic collaboration with Verge Genomics to co-develop one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. According to Mario Rovirosa, our CEO, "in line with our purpose to use business to fight for social justice, we are reinforcing our commitment to bring transformative therapeutic solutions for people living with severe and debilitating diseases”. We are Ferrer. Ferrer for good 💙💚 More info: https://lnkd.in/diWtUBMx
-
Exciting News! Verge Genomics and Ferrer are collaborating to advance VRG50635, Verge’s lead drug candidate for treating both sporadic and familial forms of #ALS. This partnership, Verge’s third with a major pharma company, underscores the value of the CONVERGE® platform in identifying novel targets for complex diseases. VRG50635 is one of the first candidate drugs to enter the clinic that was entirely discovered and developed using #AI. By combining Verge's all-in-human technology with Ferrer's global expertise in clinical development and commercialization, we aim to make a meaningful impact on those affected by ALS. For more information, read the announcement: https://bit.ly/3PA1ctA #Innovation #AIinhealthcare #DrugDevelopment
-
-
If you are attending BIO-Europe Spring, don’t miss Verge’s Jane Rhodes provide an update on our work to accelerate the drug discovery and development process using our AI-enabled CONVERGE® platform. Learn more and register here: https://bit.ly/4a2KWJC #BIOEuropeSpring #DrugDiscovery #AI #Innovation #Healthcare
-
-
On #InternationalWomensDay, Verge proudly honors the incredible contributions of women around the world and the exceptional women who play pivotal roles in driving our mission forward - not the least of which is our CEO and co-founder, Alice Zhang. Our team of exceptional women, from dedicated scientists to visionary leaders, are at the forefront of innovation, changing and defying how drug discovery is done today. We are grateful for their passion, resilience, and expertise to push the boundaries of what's possible. Happy International Women's Day to the inspiring women within Verge and beyond! #IWD2024 #WomenInSTEM
-
-
On Thursday, our Chief Medical Officer, Diego Cadavid, will join other leaders, patients, and regulatory organizations at the TRICALS Masterclass to discuss advances in clinical trial designs. If you're there, don't miss him share his expertise and experience designing innovative #ALS clinical trials. For more information, visit https://bit.ly/49Ei1ev. #clinicaltrials #innovation #ALSResearch
-